Sarepta Therapeutics (SRPT) Receives News Sentiment Rating of 0.19
Press coverage about Sarepta Therapeutics (NASDAQ:SRPT) has trended somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sarepta Therapeutics earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.6348667675945 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Sarepta Therapeutics Inc (SRPT) Needle Moving -0.30% – Evergreen Caller (evergreencaller.com)
- $37.78 Million in Sales Expected for Sarepta Therapeutics, Inc. (SRPT) This Quarter (americanbankingnews.com)
- Sarepta Therapeutics, Inc. ($SRPT) Stock | Stock Gets Slammed On Discouraging FDA Briefing Notes – Warrior Trading News (press release) (warriortradingnews.com)
- Vanguard Group Inc Buys A Lot More Sarepta Therapeutics, Inc. (SRPT) Stock – Modern Readers (modernreaders.com)
- Zacks: Analysts Anticipate Sarepta Therapeutics, Inc. (SRPT) Will Announce Earnings of -$0.89 Per Share (americanbankingnews.com)
SRPT has been the subject of a number of research reports. Janney Montgomery Scott raised their price objective on Sarepta Therapeutics from $65.00 to $73.00 and gave the stock a “fair value” rating in a research report on Monday, July 24th. Vetr downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating and set a $36.86 price objective for the company. in a research report on Monday, May 22nd. Credit Suisse Group reiterated an “outperform” rating and issued a $64.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, June 30th. Nomura reiterated a “buy” rating and issued a $84.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, May 23rd. Finally, Zacks Investment Research downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Eight investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $61.28.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 38.25 on Wednesday. Sarepta Therapeutics has a 1-year low of $25.47 and a 1-year high of $63.73. The firm’s market capitalization is $2.46 billion. The stock has a 50 day moving average price of $37.65 and a 200 day moving average price of $33.32.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million during the quarter, compared to analysts’ expectations of $22.52 million. During the same quarter last year, the firm posted ($1.19) earnings per share. The firm’s revenue was up 350000.0% on a year-over-year basis. Equities research analysts anticipate that Sarepta Therapeutics will post ($1.16) earnings per share for the current fiscal year.
In related news, CFO Sandesh Mahatme sold 50,000 shares of the company’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $2,050,000.00. Following the completion of the transaction, the chief financial officer now directly owns 41,736 shares in the company, valued at $1,711,176. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward M. Md Kaye sold 10,000 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total transaction of $410,000.00. Following the completion of the transaction, the director now owns 62,471 shares of the company’s stock, valued at $2,561,311. The disclosure for this sale can be found here. Insiders sold 78,056 shares of company stock valued at $3,224,208 over the last quarter. 9.60% of the stock is owned by company insiders.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.